Researchers from the National Institutes of Health recently reviewed the original retinal scans of participants in both the original Age-Related Eye Disease Study as well as the second study.
What researchers discovered is that for those participants who had late-stage dry age-related macular degeneration (AMD), supplementing with an AREDS 2 formula saw a slowed progression of the disease to the wet form of macular degeneration. Study results were published in the recent edition of the journal Ophthalmology.
While researchers have known that AREDS 2 supplements help slow the progression of AMD from the intermediate stage to the late stage, they wanted to establish whether supplementation could impact the progression from intermediate to late-stage.
Late-stage AMD is marked by leaky blood vessels that can cause patients to slowly lose their central vision. Currently, the only treatment for late-stage AMD is frequent intraocular injections that only offer modest effectiveness and come with significant risks.
Visivite is proud to offer a few different AREDS 2 formulations to accommodate patients and their particular needs and sensitivies.
The researchers plan to confirm the study findings in the future with a dedicated clinical trial.
